Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment

Uveal melanoma (UM) is the most common malignant intraocular tumour in adults [1]. As an orphan cancer, UM has a high medical need, which is not met so far. More than half of the patients develop distant metastases during the course of the disease, affecting predominantly the liver. Once distant metastases have occurred, the prognosis is dismal with a median overall survival (mOS) of approximately 1 year across all therapeutic regimens [2]. In contrast to the treatment of metastatic cutaneous melanoma, treatment options including kinase inhibitors, anti-CTLA-4 antibody, and anti-PD-(L)1 antibody were not able to improve the prognosis of patients with metastatic UM [3,4] and no consensus on the choice of treatment exists [5].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research